Top MarketRank™ StocksTop MarketRank™NASDAQ:MEDP Medpace (MEDP) Stock Price, News & Analysis $351.67 +6.73 (+1.95%) (As of 09/13/2024 ET) Add Compare Share Share Today's Range$343.59▼$351.8550-Day Range$327.80▼$457.2952-Week Range$227.21▼$459.77Volume298,978 shsAverage Volume248,955 shsMarket Capitalization$10.90 billionP/E Ratio35.85Dividend YieldN/APrice Target$423.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Medpace alerts: Email Address Medpace MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside20.3% Upside$423.00 Price TargetShort InterestHealthy3.39% of Float Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment0.81Based on 13 Articles This WeekInsider TradingN/AProj. Earnings Growth11.15%From $11.66 to $12.96 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.94 out of 5 starsMedical Sector12th out of 922 stocksCommercial Physical Research Industry1st out of 12 stocks 3.4 Analyst's Opinion Consensus RatingMedpace has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageMedpace has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Medpace's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.39% of the float of Medpace has been sold short.Short Interest Ratio / Days to CoverMedpace has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Medpace has recently decreased by 9.59%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMedpace does not currently pay a dividend.Dividend GrowthMedpace does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedpace has received a 72.85% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Medical devices engineering", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Medpace is -0.62. Previous Next 2.7 News and Social Media Coverage News SentimentMedpace has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Medpace this week, compared to 8 articles on an average week.Search InterestOnly 3 people have searched for MEDP on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medpace insiders have not sold or bought any company stock.Percentage Held by Insiders20.30% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medpace's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Medpace are expected to grow by 11.15% in the coming year, from $11.66 to $12.96 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medpace is 35.85, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 121.60.Price to Earnings Ratio vs. SectorThe P/E ratio of Medpace is 35.85, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 128.26.Price to Earnings Growth RatioMedpace has a PEG Ratio of 1.74. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioMedpace has a P/B Ratio of 19.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Medpace's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… One company holds a near-total monopoly on this technology. Elon Musk is one of the few people who knows this. That’s why in his recent interview with Trump, he brought up this technology as a viable solution to America’s growing energy needs. What is this technology and why has it put Elon in the middle of an ideological war with the elites?Watch my new exposé and find out. About Medpace Stock (NASDAQ:MEDP)Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.Read More MEDP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEDP Stock News HeadlinesSeptember 12 at 5:03 AM | americanbankingnews.comMedpace's (MEDP) "Outperform" Rating Reaffirmed at William BlairSeptember 10, 2024 | stockhouse.comThe Schall Law Firm Is Looking Into Whether Medpace Holdings, Inc. Violated Securities Laws And Affected Investors Are Urged To Reach OutSeptember 14, 2024 | Porter & Company (Ad)War on Elon Escalates… One company holds a near-total monopoly on this technology. Elon Musk is one of the few people who knows this. That’s why in his recent interview with Trump, he brought up this technology as a viable solution to America’s growing energy needs. What is this technology and why has it put Elon in the middle of an ideological war with the elites?September 9, 2024 | americanbankingnews.comMedpace Holdings, Inc. (NASDAQ:MEDP) Given Average Recommendation of "Moderate Buy" by AnalystsSeptember 6, 2024 | stockhouse.comMedpace Holdings, Inc. May Have Committed Securities Fraud And Stockholders Are Encouraged To Assist The Schall Law FirmSeptember 6, 2024 | americanbankingnews.comMedpace (NASDAQ:MEDP) Upgraded by StockNews.com to BuySeptember 3, 2024 | finance.yahoo.comMedpace (MEDP) Stock Moves -1.52%: What You Should KnowAugust 29, 2024 | globenewswire.comMedpace Holdings (MEDP) Reveals “Shocking” Bookings Miss, Shares Fall - Hagens BermanSeptember 14, 2024 | Porter & Company (Ad)War on Elon Escalates… One company holds a near-total monopoly on this technology. Elon Musk is one of the few people who knows this. That’s why in his recent interview with Trump, he brought up this technology as a viable solution to America’s growing energy needs. What is this technology and why has it put Elon in the middle of an ideological war with the elites?August 28, 2024 | benzinga.comInsider Decision: Robert O Kraft Exercises Options At Medpace Hldgs For $2.78MAugust 26, 2024 | globenewswire.comMedpace Holdings (MEDP) Reveals “Shocking” Bookings Miss, Shares Fall - Hagens BermanAugust 25, 2024 | stockhouse.comAn Investigation For Securities Fraud Has Been Launched Into Medpace Holdings Inc And The Schall Law Firm Is Seeking Stockholders To ParticipateAugust 20, 2024 | ca.finance.yahoo.comMEDP Sep 2024 380.000 putAugust 20, 2024 | ca.finance.yahoo.comMEDP Sep 2024 460.000 callAugust 20, 2024 | seekingalpha.comMedpace: Continued Business Growth With Asymmetrical Payoff OpportunityAugust 17, 2024 | finance.yahoo.comMEDP Sep 2024 420.000 put (MEDP240920P00420000)August 15, 2024 | globenewswire.comMedpace Holdings (MEDP) Reveals “Shocking” Bookings Miss, Shares Fall - Hagens BermanAugust 15, 2024 | finance.yahoo.comSkanska builds new office building in Cincinnati, Ohio, USA, for USD 164M, about SEK 1.7 billionSee More Headlines Receive MEDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/22/2024Today9/14/2024Next Earnings (Estimated)10/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBusiness Services Current SymbolNASDAQ:MEDP CUSIPN/A CIK1668397 Webwww.medpace.com Phone(513) 579-9911Fax513-579-0444Employees5,900Year FoundedN/APrice Target and Rating Average Stock Price Target$423.00 High Stock Price Target$452.00 Low Stock Price Target$336.00 Potential Upside/Downside+20.3%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$9.81 Trailing P/E Ratio35.85 Forward P/E Ratio30.16 P/E Growth1.74Net Income$282.81 million Net Margins16.74% Pretax Margin19.57% Return on Equity55.14% Return on Assets19.82% Debt Debt-to-Equity RatioN/A Current Ratio0.88 Quick Ratio0.88 Sales & Book Value Annual Sales$1.89 billion Price / Sales5.78 Cash Flow$10.59 per share Price / Cash Flow33.21 Book Value$18.22 per share Price / Book19.30Miscellaneous Outstanding Shares31,000,000Free Float24,693,000Market Cap$10.90 billion OptionableOptionable Beta1.35 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. August James Troendle M.D. (Age 68)Chairman & CEO Comp: $1.65MMr. Jesse J. Geiger BBA (Age 50)CPA, President Comp: $945.08kMr. Kevin M. Brady (Age 49)CFO & Treasurer Comp: $690.48kMs. Susan E. Burwig BSN (Age 61)MA, Executive Vice President of Operations Comp: $1.12MMr. Stephen P. Ewald J.D. (Age 55)Chief Compliance Officer, General Counsel & Corporate Secretary Comp: $914.64kBrandon EbkenChief Information OfficerMs. Lauren MorrisAssociate Director of Investors RelationsMr. Todd MeyersVice President of Business Development & MarketingJohn T. Wynne MBASenior Vice President of Commercial Operations & Clinical Pharmacology UnitMr. Reinilde Heyrman M.D. (Age 63)Chief Medical Officer of Medical Department More ExecutivesKey CompetitorsPRA Health SciencesNASDAQ:PRAHExelixisNASDAQ:EXELSyneos HealthNASDAQ:SYNHLaboratory Co. of AmericaNYSE:LHNational ResearchNASDAQ:NRCView All CompetitorsInsiders & InstitutionsNewbridge Financial Services Group Inc.Bought 396 shares on 9/11/2024Ownership: 0.001%Sanctuary Advisors LLCBought 3,399 shares on 9/5/2024Ownership: 0.011%Clearbridge Investments LLCBought 143,481 shares on 8/27/2024Ownership: 1.304%Cetera Investment AdvisersBought 263 shares on 8/22/2024Ownership: 0.038%Truist Financial CorpBought 648 shares on 8/21/2024Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions MEDP Stock Analysis - Frequently Asked Questions How have MEDP shares performed this year? Medpace's stock was trading at $306.53 on January 1st, 2024. Since then, MEDP stock has increased by 14.7% and is now trading at $351.67. View the best growth stocks for 2024 here. How were Medpace's earnings last quarter? Medpace Holdings, Inc. (NASDAQ:MEDP) issued its quarterly earnings data on Monday, July, 22nd. The company reported $2.75 earnings per share for the quarter, topping analysts' consensus estimates of $2.54 by $0.21. The business's revenue for the quarter was up 14.6% compared to the same quarter last year. When did Medpace IPO? Medpace (MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers. Who are Medpace's major shareholders? Top institutional investors of Medpace include Riverbridge Partners LLC (1.73%), TD Asset Management Inc (1.65%), Renaissance Technologies LLC (1.43%) and Epoch Investment Partners Inc. (1.31%). Insiders that own company stock include Medpace Investors, Llc, August J Troendle, Susan E Burwig, Stephen P Ewald, Kevin M Brady, Ashley M Keating, Robert O Kraft and Tom C King. View institutional ownership trends. How do I buy shares of Medpace? Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Medpace own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD) and Bilibili (BILI). This page (NASDAQ:MEDP) was last updated on 9/14/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredLast Call for Crypto Summit (RSVP FREE)The Dow recently shed nearly 1,000 points in a single day… Big tech stocks are getting slaughtered… And ...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medpace Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medpace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MEDP Stock Alerts